AEterna's CEO, CBO resign

David Mazzo announced that he's resigning from AEterna Zentaris after exactly one year as CEO. Reasons for the move were not disclosed. Board chairman Juergen Ernst will serve as interim President and CEO until a replacement can be found. Senior VP and chief business officer Ellen McDonald also resigned--no word yet on who will replace her. Both resignations take effect immediately.

Additionally, the company said that it will look to sell additional non-core assets as a source of non-dilutive funding.

- read the release

ALSO: Pharmacopeia's CEO Leslie Browne has resigned in order to pursue other interests. His resignation was effective April 9. Release

Related Articles:
AEterna files iNDA. Aeterna report
AEterna Zentaris announces ZEN-012 data. AEterna report
AEterna regains rights to Cetrorelix. AEterna report

Suggested Articles

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.

The delay will enable Anixa to perform additional genetic engineering intended to boost the efficacy of the treatment in ovarian cancer.